Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma. Academic Article uri icon

Overview

abstract

  • Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

publication date

  • November 25, 2021

Research

keywords

  • Ovarian Neoplasms

Identity

Scopus Document Identifier

  • 85120165119

Digital Object Identifier (DOI)

  • 10.1016/j.trecan.2021.11.006

PubMed ID

  • 34840109

Additional Document Info

volume

  • 8

issue

  • 1